Psoriasis — supplement adjuncts to dermatological care
Psoriasis is an immune-mediated skin disease whose medical mainstays — topicals, phototherapy, methotrexate, and modern biologics — deliver skin clearance no supplement can match, so the supplements here are adjuncts to dermatology care, not an alternative. The most useful are correcting low vitamin D to a 25(OH)D of 30–50 ng/mL, omega-3 at 2–4 g/day for modest skin and real cardiovascular benefit, and bioavailable curcumin; folate is specifically valuable to reduce methotrexate side effects under a prescriber. The key caveat: a few popular products can actively worsen psoriasis — flush-form niacin and echinacea have triggered flares, and high-dose vitamin A risks toxicity — so skip them. Weight loss, smoking cessation, and a Mediterranean diet often move disease activity more than any pill.
Read this first. Moderate-to-severe psoriasis (PASI ≥10, or psoriatic arthritis) should be managed by a dermatologist. Modern biologics produce skin-clearance rates that were unthinkable a decade ago. Supplement adjuncts may help cardiovascular risk, joint symptom burden, and modest improvements in skin severity scores — but they don't replace systemic therapy in moderate-to-severe disease.
The supplements with mechanism and trial signals
Vitamin D3
Dose to a 25-OH-D target of 30–50 ng/mL; typical maintenance 1,000–2,000 IU/day
Vitamin D deficiency is common in psoriasis populations and likely contributes to disease severity. Topical vitamin D analogues (calcipotriol, calcitriol) are first-line topical therapy; oral vitamin D supplementation modestly improves PASI scores in deficient patients. Don't megadose blindly — test, target, and reassess.
Omega-3 (EPA/DHA)
2–4 g EPA+DHA daily; choose third-party-tested forms; take with meals
Multiple small trials and meta-analyses show modest PASI improvements with high-dose omega-3 supplementation. The cardiovascular side benefit is particularly relevant given the elevated cardiovascular risk in psoriasis. Effect sizes on skin are smaller than topical/systemic therapy but real.
Curcumin (bioavailable form)
1–2 g curcuminoids/day from a bioavailability-enhanced formulation (Meriva, Theracurmin, BCM-95)
Curcumin modulates NF-κB signaling, which is centrally involved in psoriatic inflammation. Small RCTs in plaque psoriasis show modest PASI score improvements when added to topical therapy. Unformulated turmeric capsules will not deliver trial-level doses; use a bioavailability-enhanced form.
Folic acid (or 5-MTHF for users on methotrexate)
1–5 mg folic acid daily under dermatologist guidance during methotrexate therapy
Folate supplementation during methotrexate therapy reduces mucositis, GI side effects, and hepatotoxicity without meaningfully reducing methotrexate's efficacy. The 5-MTHF form is preferred in users with MTHFR variants. This is a prescriber-coordinated decision; folate dosing and timing matter.
Selenium
100–200 µg/day from a yeast-based or selenomethionine form; do not exceed 400 µg/day from all sources
Some trials suggest low selenium status is associated with worse psoriasis activity; supplementation modestly improves antioxidant status. Effect on skin clearance is modest. Cap supplementation — chronic high-dose selenium is hepatotoxic and increases diabetes risk.
Berberine
500 mg 2–3× daily with meals
Psoriasis is associated with metabolic syndrome, insulin resistance, and elevated cardiovascular risk. Berberine has trial evidence for glucose, HbA1c, and lipid improvements that may be particularly relevant in this population. Don't combine without prescriber input if on metformin or rapamycin.
What to skip — common but unhelpful or risky
- "Detox" / "cleanse" supplements — irrelevant to psoriasis biology; chronic herbal additive load risks GI and hepatic adverse effects.
- High-dose vitamin A (retinol) — overlaps with prescription retinoids; risk of hypervitaminosis A and hepatotoxicity. Beta-carotene is acceptable in moderate doses but not therapeutic.
- Echinacea — has triggered psoriasis flares in some users (case reports); avoid.
- "Immune-boosting" mushroom blends in moderate-to-severe disease — particularly when on a biologic; potential immune modulation may be undesirable in either direction.
- Niacin (flush form, nicotinic acid) — can trigger flares; avoid.
- Topical "natural" remedies with no evidence — coal tar and salicylic acid are evidence-based topical adjuncts; coconut oil and aloe vera have limited specific evidence for psoriasis.
The dietary and lifestyle layer that often dominates supplements
- Weight management — body weight is one of the strongest modifiable factors in psoriasis severity. Weight loss in overweight users reduces disease activity and improves biologic responsiveness.
- Smoking cessation — smoking is a recognised psoriasis trigger and worsener.
- Alcohol moderation or cessation — particularly relevant in users on methotrexate or with comorbid metabolic syndrome.
- Mediterranean dietary pattern — has the best dietary-pattern evidence for reduced psoriasis activity, likely via combined inflammatory and metabolic effects.
- Cardiovascular risk management — blood pressure, lipid, and glycaemic control are higher-leverage than any supplement for the long-term health agenda in psoriasis.
Practical quick-start. Coordinate the medical protocol with your dermatologist (topicals, phototherapy, systemic therapy as indicated). Test and correct 25-OH-D to 30–50 ng/mL. Add omega-3 EPA/DHA 2–3 g/day for combined skin and cardiovascular benefit. Add bioavailable curcumin if seeking additional anti-inflammatory adjunct. Address weight, smoking, alcohol, and Mediterranean dietary pattern — these have the largest absolute effect of any "non-pharmacological" intervention.
What to track
PASI score at baseline and at follow-up dermatology visits. 25-OH-D level at baseline. Cardiovascular risk markers (BP, lipid panel, HbA1c) — these matter beyond psoriasis. For users on methotrexate: liver function tests, full blood count, kidney function on the prescriber's schedule. For users on biologics: latent TB screening, vaccination status, infection screening per the biologic-specific protocol.